SCHEMBL27201570

SCHEMBL27201570

O=CC(=O)c1cc(I)ccc1Br

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.37
ERN1 O75460 2/20 0.37
PTPRC P08575 1/20 0.35
PTPN2 P17706 1/20 0.35
PTPN1 P18031 1/20 0.35
PTPRA P18433 1/20 0.35
PTPRB P23467 1/20 0.35
PTPRE P23469 1/20 0.35
PTPN6 P29350 1/20 0.35
MAPK1 P28482 2/20 0.33
TDP1 Q9NUW8 2/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPT P10636 2/20 0.33
SNCA P37840 1/20 0.33
ACHE P22303 1/20 0.31
BACE1 P56817 1/20 0.31
ABL1 P00519 1/20 0.31
BCR P11274 1/20 0.31
RAF1 P04049 3/20 0.31
MAP1LC3B Q9GZQ8 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL203554 0.78 PTPN1 (0.50) PTPRCPTPN2PTPN1PTPRAPTPRB
SCHEMBL1670382 0.76 PTPN2 (0.37) ARERN1PTPRCPTPN2PTPN1
SCHEMBL8282570 0.76 ERN1 (0.42) ERN1PTPRCPTPN2PTPN1PTPRA
SCHEMBL26930859 0.76 PTPRC (0.37) ARPTPRCPTPN2PTPN1PTPRA
SCHEMBL3736638 0.73 PTPRC (0.35) ARPTPRCPTPN2PTPN1PTPRA
SCHEMBL27201535 0.73 HPGD (0.50) ALDH1A1MAPTMEN1CYP1A2POLB
SCHEMBL204305 0.72 SOS1 (0.45) ALDH1A1MAPTABL1MEN1LMNA
SCHEMBL20308954 0.72 TRPV1 (0.39) PTPRCPTPN2PTPN1PTPRAPTPRB
SCHEMBL27201517 0.71 ALDH1A1 (0.51) MAPK1TDP1ALDH1A1MAPTMEN1
Thiophene SCHEMBL28659857 0.70 PTPN2 (0.40) ARPTPN2PTPN1PTPN6TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-25 US disclosed
WO-2024073502-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS GID4, MDM2, XIAP AR 2142/4885ERN1 1734/4885PTPRC 740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.